In This Article:
Amgen (AMGN) eked past first quarter revenue estimates, posting $8.15 billion (vs. estimates of $8.05 billion), while blowing past adjusted earnings per share forecasts with a figure of $4.90 (vs. estimates of $4.25).
Yahoo Finance senior health reporter Anjalee Khemlani comes on Market Domination Overtime to dive deeper into these numbers.
To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here.
Biotech company Amgen out with first quarter results. Shares are rising just a bit. Yahoo! Finance's Angelica Conlan is joining us now with those numbers. Hey, Ange.
Hey, that's right. And they are going to be probably, uh, trading a little bit on the flatter side because they met, uh, uh, expectations on revenue. 8.1 billion is what they came in with for the quarter and then beat on earnings per share, 4.90 instead of 4.25 expected from the street. Amgen, the story there is quite a diversified portfolio. So looking good on a number of fronts and a number of drugs there, but the story that we've all been waiting for, of course, is for them to enter the obesity market and whether or not Meritide is going to carry them into, you know, really a hotter space, uh, than they currently are in. We know the company's been busy with a few deals in the last few years and looks like that's all coming to root right now with the, uh, with the good earnings that they've had for the, for the quarter.
Thanks so much, Ange. Appreciate it.
